SØBY, Sebastian et al. Pembrolizumab as first-line treatment for recurrent or metastatic head and neck squamous cell carcinoma: a multi-institutional DAHANCA cohort study. Acta Oncologica, [S. l.], v. 64, p. 1269–1275, 2025. DOI: 10.2340/1651-226X.2025.44327. Disponível em: https://medicaljournalssweden.se/actaoncologica/article/view/44327. Acesso em: 11 jul. 2026.